Filing Flows › Health Care › Intellia Therapeutics (NTLA)
Intellia Therapeutics (NTLA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Intellia Therapeutics (NTLA) Q3 2026 earnings results →
Q3 2026 Revenue down 48% year over year to $7.2M
Intellia Therapeutics made $7.2M in Q3 2026 (-48% Y/Y). Operating margin n/m, net loss $127M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $7.2M in Q3 2026, down 48% year over year and down 6% from the previous quarter.
Operating costs exceeded revenue by $122.3M, an operating margin of -1707.7%. Total costs grew 3% against a revenue fall of 48%. The fastest-growing cost line was General & admin (+51%). The quarter ended with a net loss of $127.5M, wider than the previous quarter's $106.6M loss.
Operating cash flow was −$85.4M. Non-cash charges added back $1.9M of depreciation and amortization and $14.4M of share-based compensation. Working capital and other items added $25.8M. Capital expenditures of $888K exceeded it, leaving free cash flow of −$86.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $7.2M | -48% | n/m | −$127M | −$85.4M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $7.7M | -46% | n/m | −$107M | −$83.1M |
| Q1 2026 | 10-Q | May 11, 2026 | $15.0M | -10% | -668.1% | −$96.2M | −$117M |
| Q4 2025 | 10-K | Feb 26, 2026 | $23.0M | +79% | -428.9% | −$95.8M | −$69.3M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $13.8M | +51% | -808.9% | −$101M | −$76.9M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $14.2M | +105% | -772.2% | −$101M | −$99.6M |
| Q1 2025 | 10-Q | May 8, 2025 | $16.6M | -42% | -726.6% | −$114M | −$149M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Intellia Therapeutics
Intellia Therapeutics, Inc. (“we,” “us,” “our,” “Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease. For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles (“LNPs”), to develop novel, first-in-class product candidates.
In its own words, from its 10-K, filed Feb 26, 2026.
Intellia Therapeutics against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -48% against the peers' median +2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| AWHL Aspira Women's Health | Q2 2026 | $2.0M | -15% | -89.7% |
Source: Intellia Therapeutics 10-Q on SEC EDGAR · CIK 1652130 · In Vitro & In Vivo Diagnostic Substances
Guidance and outlook
13F: who owns NTLA and who is buying
More on NTLA
- How Intellia Therapeutics makes money: revenue by segment
- Intellia Therapeutics next earnings date and what analysts expect
- Intellia Therapeutics stock forecast, price target and fair value
- Who owns Intellia Therapeutics stock: holders, funds and Congress trades
- Intellia Therapeutics guidance and outlook
- Intellia Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results